Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?

被引：18

作者：

Templeton, I. E. ^{[1
]}

Chen, Y. ^{[1
]}

Mao, J. ^{[1
]}

Lin, J. ^{[2
]}

Yu, H. ^{[3
]}

Peters, S. ^{[4
]}

Shebley, M. ^{[5
]}

Varma, M. V. ^{[2
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] Pfizer Inc, Groton, CT 06340 USA

[3] Boehringer Ingelheim Pharmaceut, Ridgefield, CT USA

[4] AstraZeneca, Molndal, Sweden

[5] AbbVie Inc, N Chicago, IL USA

来源：

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2016年 / 5卷 / 10期

关键词：

D O I：

10.1002/psp4.12110

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This subteam under the Drug Metabolism Leadership Group (Innovation and Quality Consortium) investigated the quantitative role of circulating inhibitory metabolites in drug-drug interactions using physiologically based pharmacokinetic (PBPK) modeling. Three drugs with major circulating inhibitory metabolites (amiodarone, gemfibrozil, and sertraline) were systematically evaluated in addition to the literature review of recent examples. The application of PBPK modeling in drug interactions by inhibitory parent-metabolite pairs is described and guidance on strategic application is provided.

引用

页码：505 / 515

页数：11

共 50 条

[31] Physiologically Based Pharmacokinetic Modeling of Nilotinib for Drug-Drug Interactions, Pediatric Patients, and Pregnancy and Lactation
Liu, Xiaomei I.
Leong, Ruby
Burckart, Gilbert J.
Dallmann, Andre
JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (03): : 323 - 333
[32] Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
Nina Hanke
José David Gómez-Mantilla
Naoki Ishiguro
Peter Stopfer
Valerie Nock
Pharmaceutical Research, 2021, 38 : 1645 - 1661
[33] Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling
Samant, Tanay S.
Huth, Felix
Umehara, Kenichi
Schiller, Hilmar
Dhuria, Shyeilla, V
Elmeliegy, Mohamed
Miller, Michelle
Chakraborty, Abhijit
Heimbach, Tycho
He, Handan
Ji, Yan
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (03) : 575 - 585
[34] Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir
Stader, Felix
Battegay, Manuel
Marzolini, Catia
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) : 1231 - 1239
[35] PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF DISPOSITION AND DRUG-DRUG INTERACTIONS FOR VALPROIC ACID/DIVALPROEX
Reed, R.
Conner, T.
Zhang, T.
EPILEPSIA, 2017, 58 : S158 - S159
[36] Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens
Cohen-Rabbie, Sarit
Zhou, Li
Vishwanathan, Karthick
Wild, Martin
Xu, Sherrie
Freshwater, Tomoko
Jain, Lokesh
Schalkwijk, Stein
Tomkinson, Helen
Zhou, Diansong
JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (11): : 1493 - 1504
[37] Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs)
Peng Duan
Ping Zhao
Lei Zhang
European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42 : 689 - 705
[38] Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs)
Duan, Peng
Zhao, Ping
Zhang, Lei
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (04) : 689 - 705
[39] Are Circulating Metabolites Important in Drug-Drug Interactions?: Quantitative Analysis of Risk Prediction and Inhibitory Potency
Yeung, C. K.
Fujioka, Y.
Hachad, H.
Levy, R. H.
Isoherranen, N.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (01) : 105 - 113
[40] Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
Hanke, Nina
Gomez-Mantilla, Jose David
Ishiguro, Naoki
Stopfer, Peter
Nock, Valerie
PHARMACEUTICAL RESEARCH, 2021, 38 (10) : 1645 - 1661

← 1 2 3 4 5 →